Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Prospective Study to esTIMAte the Rates of Outcomes in Patients Undergoing PCI (Percutaneuos Coronary Intervention) With Drug Eluting Stent (DES) Implantation Who Take Statins (OPTIMA II) - Follow-up

NCT02099565 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02099565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02099565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Prospective Study to esTIMAte the Rates of Outcomes in Patients Undergoing PCI (Percutaneuos Coronary Intervention) With Drug Eluting Stent (DES) Implantation Who Take Statins (OPTIMA II) - Follow-up
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
May 31, 2014
Completion date
April 30, 2015
Enrollment
572 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

major adverse cardiovascular and cerebrovascular events (macce)